




RealRate

PHARMACEUTICAL 2016

Globestar Therapeutics Corp
Rank 275 of 295



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2016

Globestar Therapeutics Corp Rank 275 of 295

The relative strengths and weaknesses of Globestar Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Globestar Therapeutics Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Globestar Therapeutics Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 58%, being 205% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	11
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	247
Liabilities, Non-Current	0
Other Assets	311
Other Compr. Net Income	3.9
Other Expenses	562
Other Liabilities	63
Other Net Income	42
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	566

Output Variable	Value in 1000 USD
Assets	322
Liabilities	310
Expenses	1,128
Revenues	0
Stockholders Equity	13
Net Income	-1,086
Comprehensive Net Income	-1,084
BaseVar	903
ECR before LimitedLiability	-334%
Economic Capital Ratio	58%